Catalent
 
2Q Revenues: $454.9 million (flat)

2Q Earnings: $30.6 million (-33%)

YTD Revenues: $877.9 million (flat)

YTD Earnings: $39.5 million (+51%)

Comments: Revenue from the Oral Technologies segment was $255.1 million in the quarter, down 8%, attributable to the temporary suspension of operations of the Beinheim facility, lower demand for certain modified release technologies, partially offset by increased demand for certain softgel products. Revenue from the Development and Clinical Services segment was $131.6 million, up 22% driven by analytical services, the timing of resolution of volume commitments and increased sales volumes for integrated oral solids development and manufacturing, as well as growth in clinical services and the impact of the Micron acquisition. Revenue from the Medication Delivery Solutions segment was $71.1 million, down 4%, with increased demand for the blow-fill-seal technology platform, partially offset by the timing of resolution of volume commitments and decreased demand for injectable products at the company’s European pre-filled syringe operations.